US Stock Insider Trading | Baimalin Pharmaceuticals disclosed one insider transaction on March 12

On March 12, 2026, BioMarin Pharmaceutical (BMRN) disclosed 1 insider trading transaction involving company insiders. Executive Guyer Charles Greg sold 16.5k shares on March 11, 2026.

【Recent Insider Transactions】

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 12, 2026 Executive Guyer Charles Greg March 11, 2026 Sell 16.5k 60.46 996.7k
February 26, 2026 Executive Friberg Gregory R February 26, 2026 Sell 6326 60.38 381.9k
February 26, 2026 Executive Davis George Eric February 26, 2026 Sell 26.1k 61.36 1.5991M
February 13, 2026 Executive Guyer Charles Greg April 30, 2025 Buy 317 54.14 17.2k
February 13, 2026 Executive Davis George Eric April 30, 2025 Buy 375 54.14 20.3k
February 13, 2026 Executive Guyer Charles Greg October 31, 2025 Buy 62 45.54 2823.17
February 13, 2026 Executive Mueller Brian April 30, 2025 Buy 375 54.14 20.3k
February 13, 2026 Executive Hubbard Cristin October 31, 2025 Buy 80 45.54 3642.80
February 13, 2026 Executive Friberg Gregory R October 31, 2025 Buy 398 45.54 18.1k
December 2, 2025 Director Hardy Alexander April 30, 2025 Buy 375 54.14 20.3k

【Company Profile】

Biomarin Pharmaceutical Inc. was incorporated in Delaware in October 1996 and began operations on March 21, 1997. The company is a global biotechnology company dedicated to turning the promise of gene discoveries into drugs that will have a profound impact on the lives of every patient. T. BioMarin selects candidate products for diseases and conditions with significant unmet medical needs—these diseases and conditions have a strong biological understanding and offer opportunities to be first to market or to provide products that are better than existing ones. The company’s product portfolio consists of four approved products and multiple research pipeline candidate products.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin